top of page

Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure

sharonshieldsconsu
Nov 12
3 min read

Earlier this week I examined the Q3 Pharma landscape, I now turn to MedTech, another area I have always worked in and enjoyed.


Medtech’s Q3 story differs from pharma’s: growth is shaped less by a single product category and more by procedure volumes, hospital spending, and demand for differentiated technologies.


Companies such as Boston Scientific, Intuitive Surgical, and Stryker illustrate areas that have benefited from demand for innovative, procedure-linked products.


By contrast, QuidelOrtho, with its exposure to COVID-era testing, and Philips, which has faced business-specific challenges including the Respironics recall and softer demand in some markets, illustrate pressures that can weigh on medtech companies.


These are a few examples that show the differing picture, as the Q3 results and analysis is published.


Where momentum is strongest?


Procedure-driven and high-acuity devices


Businesses connected to surgical and interventional procedures can benefit from ongoing demand in areas such as cardiology, orthopedics, neurovascular care, and advanced wound care.


For example, Boston Scientific has exposure to fast-growing areas including electrophysiology and cardiovascular devices. Stryker benefits from demand for orthopedic products and surgical technologies, while Intuitive Surgical is a prominent example of a company built around robotic-assisted procedures. Their results still depend on factors such as procedure growth, product adoption, and hospital purchasing decisions.


Robotic medical device and brain scan image
Robotics offer further growth opportunities within the MedTech sector

Diabetes technology and other growth niches


Diabetes technology is another important growth area. Abbott and Dexcom, for example, are known for continuous glucose monitoring products. Wider adoption and product innovation can support growth, though competition and reimbursement conditions matter.

Robotics and neuromodulation also offer opportunities for companies with differentiated products and strong clinical adoption. However, even innovative technologies can be affected by hospital budgets, particularly when purchases involve significant upfront investment.


Recurring-revenue business models

Companies with revenue from consumables, implants, single-use devices, and service contracts may have more predictable sales than those relying primarily on occasional large equipment purchases. Abbott’s diabetes products and Boston Scientific’s interventional device business are examples of areas where recurring product demand can be important.


Areas under pressure


Capital-intensive equipment

Companies selling imaging systems and other large hospital equipment can be affected when customers delay major purchases. Philips and Siemens Healthineers are examples of businesses with substantial imaging and diagnostic equipment operations. Their performance can vary by region and product line, so it is important to distinguish company-wide results from individual segment trends.


COVID-exposed diagnostics

Companies that benefited from pandemic testing have faced difficult comparisons as COVID-testing demand normalized. QuidelOrtho is an example of a diagnostics company with exposure to this market. The key question for such companies is how successfully they can grow other testing products and offset declining pandemic-related demand.


Commoditized products

Companies competing mainly on price in crowded device categories may face pressure from hospital purchasing groups and lower-cost competitors. Without clear clinical or workflow advantages, protecting margins can be difficult.


What to take away


Medtech’s potential winners tend to have differentiated products, exposure to growing procedure volumes, or dependable recurring revenue. Companies under greater pressure may be more exposed to declining COVID-testing demand, slower capital-equipment purchases, or price competition.


Medical Diagnostics test being carried out in a lab by a scientist
Diagnostics Companies faced challenges in 2026

Boston Scientific, Intuitive Surgical, Stryker, Abbott, and Dexcom are useful examples of companies associated with growth-oriented medtech categories. QuidelOrtho and Philips illustrate some of the challenges that can affect diagnostics and equipment businesses. There are winners, laggards and those showing mixed performance based on Q3 revenues and operating trend, rather than share price performance.


What this means for talent


Medtech’s uneven growth is changing the skills companies need. Businesses expanding in procedure-driven technologies—such as robotics, electrophysiology, structural heart, and diabetes devices—need talent in R&D, clinical evidence, regulatory affairs, and product development, as well as field-based clinical specialists who can support adoption in hospitals. As devices become more connected and software-enabled, expertise in data, software, AI, and cybersecurity is also increasingly important.


For companies facing slower equipment sales, declining COVID-testing demand, or pricing pressure, the challenge is to adapt the workforce while controlling costs. That may mean reskilling or redeploying employees toward faster-growing product lines, digital services, and new diagnostic markets. Overall, companies that align talent with areas of clinical demand—and retain the specialized expertise needed to bring products to market—will be better placed to sustain growth.


If you wish to discuss your Medtech talent strategy please contact Sharon Shields Consulting.

References


Company results and business updates

Sector and workforce context

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page